Abstract
Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave®, Mysimba™) is an effective adjunct to reduced-calorie diet and increased physical activity for chronic bodyweight management in adults who are either obese, or overweight with at least one bodyweight-related co-morbidity. It provides combination treatment with an opioid antagonist (naltrexone) and a weak dopamine and norepinephrine reuptake inhibitor (bupropion), which synergistically interact in the CNS to control appetite and food intake. In clinical trials in obese adults or overweight adults with controlled hypertension and/or dyslipidaemia (± type 2 diabetes), naltrexone ER/bupropion ER improved bodyweight-related outcomes to a significantly greater extent than placebo, and was generally well tolerated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.